RxDoctor Payments DataLook up a doctor →

David Lee, MD

Interventional Cardiology · Stanford, CANPI 1619003860

Payments from drug & device makers

$5,701,340in general payments, 2019–2025

Across 468 payments — averaging $12,182 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5.6M
  • Abbott$52K
  • Boston Scientific$18K
  • Philips North America LLC$13K
  • GE HealthCare$8K
  • Cardiva Medical, Inc.$3K
  • plus $896 from 5 others
$11,375in research payments, 2019–2025

Across 8 payments — averaging $1421.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$11K

What the payments were for

  • Consulting fees$101,63844%
  • Speaking & faculty fees$57,37525%
  • Travel & lodging$62,44327%
  • Food & beverage$9,3634%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,701,340 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$143,548
Medicare patients
365
Services billed
821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab17$27,187
EliquisApixaban16$21,914
BrilintaTicagrelor11$6,605
ClopidogrelClopidogrel Bisulfate79$1,437
Rosuvastatin Calcium62$1,249
Ezetimibe24$842
Atorvastatin Calcium94$748
Isosorbide Mononitrate ErIsosorbide Mononitrate38$614
Metoprolol Succinate25$535
Nebivolol Hcl12$514
Nitroglycerin20$294
Losartan Potassium27$275
Pravastatin Sodium18$191
Carvedilol31$143
Metoprolol Tartrate17$138

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →